质疑工业资助与非工业资助的类风湿关节炎生物制剂及小分子药物随机对照试验之间的发表偏倚
该系统综述检索评估类风湿关节炎(RA)生物制剂及小分子药物随机对照试验(RCT)中,工业资助与非工业资助之间是否存在发表偏倚,以及阳性结果与阴性结果RCT的发表差异。共纳入349项RCT,其中297项(85.18%)为商业资助;商业与非商业资助RCT在阳性结果发表上无显著差异,样本量是预测高影响因子期刊发表的唯一显著参数。
要点
- 85.18%(297/349)的RCT为商业资助,商业与非商业资助在阳性结果发表上无显著差异。
- 商业资助RCT和阳性结果RCT的样本量显著更大。
- 样本量是预测RCT发表于RA领域高影响因子期刊的唯一显著参数。
核心结论
- 商业资助与阳性结果发表或RCT发表于高影响因子期刊之间无显著关联。
研究设计与样本
- comprehensive systematic literature review,纳入349项FDA批准的生物制剂及小分子药物治疗RA的RCT,每项RCT分类为阳性或阴性结果、商业资助或非商业资助。
主要发现
- 297/349(85.18%)的RCT为商业资助。
- 商业资助与非商业资助RCT在阳性结果或发表关联上无显著差异。
- 商业资助RCT和阳性结果RCT的样本量显著更大。
- 样本量是预测RCT发表于RA领域高影响因子期刊的唯一显著参数。
临床怎么用
- 解读RA生物制剂及小分子药物RCT证据时,商业资助不应被视为阳性结果发表偏倚的独立警示信号。
- 评估RCT发表期刊影响因子时需考虑样本量这一显著预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There has been a significant increase in financial support of clinical research by the pharmaceutical industry. METHODS: We performed a comprehensive systematic literature review to determine whether there is publication bias for rheumatoid arthritis (RA) studies between industry-funded and non-industry funded randomized controlled trials (RCTs), and between RCTs with positive results (PRs) and those with negative results (NRs) of FDAapproved biological and small molecule drug therapy for RA. Each RCT was classified as having either a PR or a NR, and as having received commercial funding or not. RESULTS: Most (297/349, 85.18%) of the RCTs were commercially funded. There was no significant difference in PRs or association with publication between commercially and noncommercially funded RCTs. Sample size was significantly larger in commercially funded RCTs and in those with PRs, and it was the only significant parameter that predicted publication in higher impact factor journals in the field of RA. CONCLUSION: There is no significant association between commercial funding and the publication of positive results or the publication of an RCT in higher impact factor journals.
引用
- Cohen N, Lavie RG, Manor Y, et al. Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritis. Semin Arthritis Rheum. 2019. PMID: 31280935. doi:10.1016/j.semarthrit.2019.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。